INTRODUCTION
SHARPIN is a widely expressed cytosolic protein that, together with HOIL-1L interacting protein and HOIL-1L, forms the linear ubiquitin chain assembly complex (LUBAC) (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011) . The ternary LUBAC complex catalyzes the formation of linear polyubiquitin chains, which regulate cell signaling, most notably the canonical nuclear factor (NF)-kB activation in response to stimuli like tumor necrosis factor (TNF).
A spontaneous SHARPIN-null mutation in Sharpin cpdm mice manifests with a progressive multiorgan inflammatory phenotype (HogenEsch et al., 1993; Seymour et al., 2007) . The most prominent feature in these mice is chronic proliferative dermatitis resembling psoriasis, but the mice also display leukocytosis, inflammation in many other organs (gastrointestinal track, liver, etc.) , splenomegaly, abnormal development of Peyer's patches, hypoimmunoglobulinemia, and defective Th1 cytokine production. The complex Sharpin cpdm phenotype is partially linked to signaling and cytokine defects. Thus, the skin inflammation can be reversed by crossing Sharpin cpdm mice with TNFdeficient mice (Gerlach et al., 2011) . This is thought to be due to elimination of the increased LUBAC-dependent cell-death sensitivity of Sharpin cpdm keratinocytes upon TNF triggering and subsequent alleviation of secondary inflammatory response. Sharpin cpdm mice also have decreased secretion of proinflammatory cytokines (e.g., interferon-g, interleukin [IL]-6, and IL-12) and increased secretion of Th2-type cytokines (IL-5; Renninger et al., 2010; Wang et al., 2012; Zak et al., 2011) . However, the noncutaneous lymphoid aberrations are not affected by TNF elimination (Gerlach et al., 2011) , mice deficient for HOIL-1 (another LUBAC component) do not appear to display any overt inflammatory phenotype (Tokunaga et al., 2009) , and pharmacological inhibition of NF-kB signaling only partially alleviates the skin inflammation (Liang et al., 2011) . Moreover, although blockade of IL-5 virtually eliminates eosinophils from Sharpin cpdm mice, it does not affect the inflammation phenotype (Renninger et al., 2010) . It is therefore tempting to speculate
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Chemokine-triggered leukocyte migration on endothelial cells is one crucial step during the leukocyte traffic into sites of inflammation (Ley et al., 2007; Vestweber, 2012) . Given that SHARPIN has previously been reported to inhibit b1-integrins in cancer cells (Rantala et al., 2011) , we asked whether SHARPIN could regulate leukocyte locomotion in inflammation. Here, we observed that SHARPIN strongly localizes to the trailing edges (called uropods in leukocytes) of migrating lymphocytes and controls uropod detachment and cell locomotion. In migrating lymphocytes, the leading edge and the midcell zone are thought to display active lymphocyte-function-associated antigen-1 (LFA-1, a heterodimeric aLb2-integrin expressed on practically all leukocytes) capable of binding to intercellular adhesion molecule-1 (ICAM-1) and other ligands. Uropods, in contrast, express inactive LFA-1, which facilitates cellular detachment (Morin et al., 2008; Smith et al., 2005; Stanley et al., 2008) . However, the mechanisms of uropodial LFA-1 deactivation have remained unknown. We now show that SHARPIN regulates lymphocyte polarity by directly interacting and deactivating LFA-1. Thus, our data reveal SHARPIN as a regulator of uropod detachment, which is the final checkpoint in leukocyte extravasation, and suggest a mechanism that dynamically controls deactivation of leukocyte integrins.
RESULTS
Impaired Uropod Detachment in SHARPIN-Deficient Lymphocytes SHARPIN-deficient Sharpin cpdm mice manifest with aberrant leukocyte infiltrations in many organs, and therefore, we studied whether SHARPIN would play a role in leukocyte locomotion. We found that endogenous SHARPIN is preferentially localized to the detached uropods, together with an established uropod marker CD44, in chemokine C-X-C-motif ligand 12 (CXCL12) -activated wild-type splenocytes migrating on recombinant mouse ICAM-1 ( Figure 1A ). Sharpin cpdm splenocytes, which, as expected, lacked anti-mouse SHARPIN antibody reactivity, were flatter and displayed a loss of distinctive uropod structures, showing instead elongated trailing edges adherent to the substrate. SHARPIN-deficient splenocytes and thymocytes adhered to and spread on ICAM-1 significantly better than wild-type cells ( Figures 1B and 1C) . Furthermore, lymphocyte migration on ICAM-1 was regulated by SHARPIN in a substrateconcentration-dependent manner ( Figure 1D ). When low levels of ICAM-1 substrate (0.5-5 mg/ml) were used, CXCL12-stimulated Sharpin cpdm lymphocytes migrated significantly faster than wild-type cells. However, at a high ICAM-1 concentration (50 mg/ml), SHARPIN-deficient lymphocytes migrated much slower than the wild-type cells. Purified CD4+ T cells from Sharpin cpdm mice also migrated faster on low ICAM-1 concentration and slower on high ICAM-1 concentration than purified wild-type CD4+ cells ( Figure 1E ; Movie S1). Sharpin cpdm cells migrating on high ICAM-1 concentration had more extended tails than wild-type cells and showed an abnormally strongly polarized morphology ( Figure 1F ). Moreover, the uropod/tail lifetime was significantly longer for lymphocytes lacking SHARPIN, and consequently, the SHARPIN-deficient cells showed impaired detachment from the matrix ( Figure 1F ; Movie S2). Wild-type cells migrating on high ICAM-1 concentration (50 mg/ml) showed preferential localization of SHARPIN and CD44 to uropods and phalloidin staining revealed typical cortical F-actin enriched in the uropods, whereas talin (an integrin activator normally polarized to the cell front [Gó mez-Mó uton et al., 2001 ]) accumulated at the leading edges ( Figure 1G ). In Sharpin cpdm cells, in contrast, CD44 and talin both distributed more evenly throughout the cells, and the strongly elongated tails were positive for filamentous actin throughout the tails.
Lymphocytes bind to ICAM-1 mainly via LFA-1 (Hogg et al., 2011) . Integrin-mediated cell migration is dependent on receptor expression levels, receptor activity, and ligand density (following a bell-shaped curve), and detachment of trailing edges of cells requires disassembly of integrin-containing adhesions (Constantin et al., 2000; Franco et al., 2004; Palecek et al., 1997) . Therefore, the increased migration speed on low ICAM-1 concentration and the elongated tails on high ICAM-1 concentration in Sharpin cpdm lymphocytes could be indicative of higher LFA-1 expression levels or activity. We found that aLb2 (LFA-1) integrin was expressed on practically all thymocytes and splenocytes (92%-95%; n = 7-8 mice/group) of both wild-type and Sharpin cpdm mice, and the levels were comparable (thymocytes and CD4+ splenocytes) or slightly lower (total splenocytes) on Sharpin cpdm cells (Figures 2A and 2B ).
The expression of other integrins (aM/CD11b, aX/CD11c, and a4/CD49d) and the numbers of CD4+ and CD8+ T cells, B220+ B cells, CD4+CD25+FoxP3+ T regulatory cells, and cells expressing chemokine receptors (CXCR4, CCR7, and CCR9) and activation markers (CD25 and L-selectin) were also similar in spleen and thymus of wild-type and Sharpin cpdm mice, with the exception of minor changes in the numbers of CD4+ cells and CD49d-positive cells among total splenocytes (Figures S1A-S1F; data not shown). Notably, among CD4+ splenocytes, (B and C) Adhesion (B) and spreading (C) of wild-type and Sharpin cpdm splenocytes and thymocytes on ICAM-1 (5 mg/ml).
(D and E) Migration of CXCL12-stimulated, wild-type, and Sharpin cpdm (D) splenocytes and (E) purified CD4+ T cells on different concentrations of ICAM-1.
Representative cell tracks and cumulative data are shown. See also Movies S1 and S2. (F) Phenotype of the uropods in cells migrating on high ICAM-1 concentration (50 mg/ml) was determined using image analyses. Extended uropod defines a uropod length >33% of cell body diameter, polarity index is the ratio of the longest leading-edge-to-uropod distance divided by the longest width of the cell, and uropod lifetime is the time difference between uropod appearance and disappearance. The scale bars represent 10 mm. the expression of aM/CD11b and CD49d was similar in both genotypes. Together, these data show that the lymphocyte phenotypes of wild-type and Sharpin cpdm lymphocytes are relatively similar and that SHARPIN preferentially localizes to uropods in migrating lymphocytes and regulates uropod stability, adhesion to the substrate, and migration velocity both in total splenocytes and purified CD4+ T cells.
SHARPIN Preferentially Colocalizes with Inactive LFA-1 in Uropods
To analyze the possible role of SHARPIN in regulating LFA-1 activity, we used human cells, for which reporter antibodies for LFA-1 activity are available. In freshly isolated human peripheral blood mononuclear cells (PBMCs) and in CXCL12-stimulated PBMC binding to recombinant ICAM-1, stainings with specific SHARPIN antibodies (Figures S1G and S1H) showed SHARPIN to be evenly distributed in the cytoplasm of nonpolarized cells ( Figures 2C and 2D ). In contrast, in polarized cells (>100 cells analyzed) endogenous SHARPIN was always concentrated in, but not restricted to, the uropods ( Figures 2D and S1I ). GFP-SHARPIN transfected into PBMC also preferentially localized in CD44-positive uropods and was less abundant in the talinpositive leading edges ( Figures 2E and 2F ). Leukocytes migrating in a lymphoid tissue in vivo also showed enrichment of endogenous SHARPIN in the uropods ( Figure S3J ). In human cells migrating on ICAM-1, LFA-1 was found both at the leading edge and in the uropod, and endogenous SHARPIN (as well as GFP-SHARPIN) and LFA-1 partially colocalized in the uropods ( Figures 2G, S1K , and S1L). KIM127 and 24 are unique reporter monoclonal antibodies (mAbs), which specifically detect the extended, intermediate-affinity, and high-affinity forms of LFA-1, respectively (Dransfield and Hogg, 1989; Hogg et al., 2011; Robinson et al., 1992) . On freshly isolated, migrating PBMC, the KIM127 and 24 signals concentrated to the leading edge and midcell zones, whereas SHARPIN mainly localized to the uropod ( Figures 2H and 2I) . Thus, our quantitative data ( Figure 2J ) show that SHARPIN is enriched in uropods together with inactive LFA-1 in contrast to the integrin activator talin and active LFA-1, which mainly localize to the leading edge and midcell zones.
SHARPIN Interacts with LFA-1 SHARPIN has been shown to physically interact with CD29 cell adhesion receptors in cancer cells (Rantala et al., 2011) . To study whether SHARPIN can physically interact with leukocyte integrins, we cotransfected plasmids encoding aL and b2 chains of LFA-1 with GFP-SHARPIN (or GFP only as a control) into human embryonic kidney 293 (HEK293) cells. An aL antibody specifically coimmunoprecipitated GFP-SHARPIN, but not GFP ( Figure 3A ). Endogenous LFA-1 and endogenous SHARPIN from Jurkat cells and freshly isolated human PBMC also coimmunoprecipitated. LFA-1 was also detected in reciprocal immunoprecipitations with SHARPIN antibody (Figures 3B and  3C ). Activation of PBMC for 2-30 min with CXCL12 did not alter the protein levels of SHARPIN or LFA-1 ( Figure S2 ).
Purified recombinant full-length LFA-1, but not LFA-1 protein lacking the cytoplasmic domains, bound to recombinant GST-SHARPIN, but not GST alone, in pull-down assays ( Figures 3D   and 3E ). Far-western analyses confirmed this interaction (Figure 3F) . The full-length cytoplasmic sequence of aL, but not of b2, and the conserved membrane proximal part of the aL-tail synthesized as biotinylated peptides bound to GFP-SHARPIN from cell lysates ( Figure 3G ). The cytoplasmic sequences of other leukocyte integrins aM and aD (aX was insoluble) also interacted with GFP-SHARPIN ( Figure 3G ). All these experiments clearly show that SHARPIN directly binds to the cytoplasmic domain of aL.
SHARPIN Maintains LFA-1 in an Inactive Conformation and Regulates Lymphocyte Extravasation Direct interaction between SHARPIN and LFA-1 and the colocalization of inactive LFA-1 and SHARPIN in the uropods led us to study whether SHARPIN could be involved in LFA-1 inactivation. Knockdown of SHARPIN in human PBMC (on average 50%-70%) increased the adhesion of these cells to human recombinant ICAM-1, improved their migration on low ICAM-1 concentration, and inhibited their migration on high ICAM-1 concentration ( Figures 4A and 4B) . Conversely, overexpression of SHARPIN significantly reduced the expression of the LFA-1 activation epitopes KIM127 and 24 on cultured, CXCL12-stimulated PBMC in fluorescence-activated cell sorting (FACS) analyses ( Figures 4C and S3A) . Moreover, transiently expressed human LFA-1 was more active in Sharpin cpdm mouse embryonic fibroblasts (MEFs) than in wild-type MEFs (Figures 4D and S3B ). These functional data show that SHARPIN inhibits LFA-1.
To study the role of SHARPIN in lymphocyte migration in vivo, we performed competitive homing assays, in which the ability of lymphocytes to move from the blood through the vessel wall into the tissue is measured. Splenocytes from wild-type and Sharpin cpdm mice were isolated, labeled with two different intensities of a fluorescent dye (carboxyfluorescein succinimidyl ester [CFSE] ) and injected intravenously into wild-type recipients. After a 2 hr recirculation period, Sharpin cpdm lymphocytes (both total splenocytes and CD4+ lymphocytes) homed to peripheral (PLN) and mesenteric (MLN) lymph nodes with about half the efficiency of their wild-type counterparts (seven mice per group; Figures 4E and 4F) . In an independent experiment, the reduced lymph node homing of Sharpin cpdm splenocytes and CD4+ T cells was confirmed and we observed that, instead, Sharpin cpdm cells accumulated more in the spleen than wildtype cells ( Figure S3C ). Also, in microscopic analyses, fewer Sharpin cpdm lymphocytes accumulated in PLN parenchyma than wild-type cells 30 min after intravenous transfer ( Figure 4G ). Thus, absence of SHARPIN impairs lymphocyte homing to lymph nodes. The function of SHARPIN in lymphocyte transmigration was studied using time-lapse microscopy in in vitro flow chamber assays, in which human PBMCs are perfused with a defined shear stress over cultured confluent endothelial monolayers. After adhesion, control small interfering RNA (siRNA)-silenced human PBMC transmigrated (transition from white/gray to black cells in phase contrast images) through the endothelium preferentially at the endothelial cell junctions. SHARPIN localized to the uropods during the transmigration ( Figure 4H ). After completion of the transmigration, the majority of cells swiftly moved onward from the transmigration site ( Figure 4I ; Movie S3).
SHARPIN-silenced cells transmigrated with similar kinetics, but thereafter they migrated less persistently away from the transmigration sites and often had to make repetitive efforts to leave the transmigration spot below the endothelium ( Figure 4I ; Movie S3).
SHARPIN Rescues Migration and Uropod Detachment Defects of SHARPIN-Deficient Cells
Sharpin cpdm splenocytes expressing GFP-SHARPIN bound 60% less to ICAM-1 (5 mg/ml) than Sharpin cpdm splenocytes expressing GFP only ( Figure 4J) , showing that the increased adhesion of Sharpin cpdm cells on ICAM-1 was SHARPIN-dependent. Binding of Sharpin cpdm splenocytes to a non-integrin-dependent ligand (poly-L-lysine) was not affected by SHARPIN. The migration velocity of GFP-expressing Sharpin cpdm lymphocytes on ICAM-1 (5 mg/ml) was significantly higher than that of GFP-expressing wild-type cells ( Figure 4K ). Importantly, Figure 4L ). Thus, SHARPIN is causally involved in regulating uropod formation, polarization, and lymphocyte motility on ICAM-1.
DISCUSSION
This study identifies a function for SHARPIN in regulating cell polarization and uropod detachment in migrating lymphocytes. We also describe SHARPIN as the first endogenous molecule capable of inhibiting LFA-1 by binding directly to the integrin a-tail. These data show that the inactive LFA-1 conformation is not merely a passive default state in the leukocytes but is actively maintained through adjustable intracellular protein interactions. Increased LFA-1 activation epitopes associated with lack of SHARPIN expression and diminished LFA-1 activation with increased SHARPIN expression. Because SHARPIN did not alter LFA-1 expression levels, these data directly implicate SHARPIN in regulation of LFA-1 activity. Because there is always a dynamic balance between active and inactive LFA-1 on the cell membrane, SHARPIN could help to maintain LFA-1 in an inactive conformation by preventing activation and/or by deactivating the active conformation. Thus, in nonadherent and freshly adherent cells, which do not have uropods and which display even localization of SHARPIN throughout the cytoplasm, SHARPIN may function in regulating general LFA-1 adhesiveness and activation.
In migrating lymphocytes, adhesive cell-substrate contacts need to be disengaged at the trailing edge to allow net forward movement of the cell . We showed that in migrating cells SHARPIN preferentially redistributes to uropods, to which inactive LFA-1 is recruited (Morin et al., 2008; Smith et al., 2005) . The effects of SHARPIN on lymphocyte migration were dependent on the ligand concentration. Increased LFA-1 activation in the absence of SHARPIN enhanced cell migration on low ICAM-1 concentration and inhibited migration on high ICAM-1 concentration and in transmigration assays. Similarly, constitutively active LFA-1 mutant T cells (lacking the cytoplasmic domain) adhere better to ICAM-1 but show impaired transendothelial migration in vitro and migrate worse to tissues in vivo than wild-type cells (Lu and Springer, 1997; Semmrich et al., 2005) . A small-molecule agonist of LFA-1 also enhances ligand binding and inhibits transendothelial migration of lymphocytes accompanied by uropod elongation and impaired de-adhesion (Yang et al., 2006) . Also, T cells carrying a constitutively active mutant (an engineered point mutation in the extracellular domain) adhere better to ICAM-1 and yet home worse than wild-type cells to PLN and MLN in vivo (Park et al., 2010) . These data strongly implicate the role of LFA-1 activity regulation also in in vivo homing, although the contribution of slight changes in the LFA-1 expression levels was not formally excluded. In fact, LFA-1-dependent uropod elongation has very recently been proposed to be a final common step during transendothelial migration (Hyun et al., 2012) . Therefore, a release mechanism is needed before the cell can migrate further into the tissue, and we postulate that SHARPIN, which is enriched in the uropod of extravasating leukocytes, facilitates homing, and enhances cell movement after transendothelial migration, could play an important role in this process.
The results that SHARPIN-negative cells showed impaired short-term (30 min-2 hr) homing to lymph nodes and yet SHARPIN-deficient mice suffer from chronic inflammation may have several explanations. The chronic inflammatory phenotype develops during a much longer time period (the first 4-6 weeks of postnatal life; HogenEsch et al., 1993) , during which many other LFA-1 mediated inflammatory functions apart from the initial entry may become relevant. For instance, LFA-1-ICAM-1 interaction contributes to T cell costimulation (Wü lfing and Davis, 1998) and lymphocyte exit from the lymph nodes into lymphatic vasculature (Reichardt et al., 2013) , and therefore, dysregulated LFA-1 activity in Sharpin cpdm cells may modulate these processes. Finally, in vivo SHARPIN-deficient cells localized better than wild-type cells to spleen (which is one of the affected organs in Sharpin cpdm mice), implicating that the contribution of LFA-1 activity regulation may vary in different organs.
Activation of LFA is essential for its function (Abram and Lowell, 2009; Gahmberg et al., 2009; Hogg et al., 2011; Kinashi, 2007) . LFA-1 is normally found in an inactive (i.e., incompetent for ligand binding) form on leukocytes, and only after receiving activation signals, does it become functionally competent. Critical for the activation is the interaction of the cytoplasmic domain of the b chain with talin and kindlins, which leads to conformational changes of the extracellular domains in the integrin heterodimer (Moser et al., 2009; Shattil et al., 2010) . LFA-1 activation can be indirectly inhibited through certain signaling molecules, such as Cdc42, PIP5K1g90, cytokine growth differentiation factor-15, and E3 ubiquitin ligase Cbl-b, which interfere with the upstream activation signals (BolominiVittori et al., 2009; Hogg et al., 2011; Kinashi, 2007; Wernimont et al., 2010; Zhang et al., 2003) . In contrast, SHARPIN directly binds to the cytosolic membrane proximal sequence of the a-tail of LFA-1. Certain artificial deletions of the aL cytoplasmic tail increase LFA-1 activity and cell adhesion to ICAM-1 (Lu and Springer, 1997; Semmrich et al., 2005) . These mutants are predicted to be unable to bind SHARPIN, which could explain why these mutants are constitutively active.
Delineation of multiple functions and the physiological role of SHARPIN remains an important area of future investigation. It will be critical to determinate whether SHARPIN can simultaneously function as a component of the LUBAC complex and an inhibitor of integrins, possibly implicating a role for linear ubiquitination/NF-kB signaling in the regulation of integrin signaling, or whether these two binding modes are mutually exclusive. Moreover, we have shown that binding of SHARPIN to the conserved segment of the a-cytoplasmic tails of collagen and fibronectin-binding a2b1-and a5b1-integrins in cancer cells prevents recruitment of the integrin activators talin and kindlin with the b1-tail via a yet-unknown mechanism (Rantala et al., 2011) . Whether similar mechanisms operate in inhibition of LFA-1 by SHARPIN remains to be determined, but also additional mechanisms could be involved. SHARPIN thus inhibits both b1-and b2-integrins, although the activity regulation of b1-integrins in adherent epithelial and mesenchymal cells is fundamentally different from that of b2-integrins in professionally motile leukocytes. Activity regulation of b1-integrins is modulatory, because these extracellular matrix receptors are always at least partially active and strongly coupled to actin. In sharp contrast, activation of b2-integrins needs to be fully switchable from inactive to active within seconds to allow extravasation of blood-borne leukocytes. In addition, many of the integrin activators are specific for b2-integrins over b1-integrins (e.g., the guanosine triphosphatase Rap1 regulating LFA-1 vesicle traffic, RAPL regulating LFA-1 transport, and adaptor 14-3-3 binding to phosphorylated b2-integrin), and the Rap1-RAPL-dependent LFA-1 activation involves binding to the alpha-subunit cytoplasmic region of LFA-1 immediately adjacent to the SHARPIN-binding site (Hogg et al., 2011; Katagiri et al., 2003) . This suggests that SHARPIN-mediated LFA-1 inactivation may (legend continued on next page) involve mechanisms that do not play a role in the regulation of b1-integrins. However, this remains to be investigated in detail. The specific physiological contribution of SHARPIN-mediated NF-kb activation (via LUBAC) and integrin inactivation in different lymphoid and nonlymphoid tissues and at different time points also needs to be determined in the future using in vivo imaging, specific inhibitors, and cell-type-specific conditional knockouts.
In conclusion, we have shown that SHARPIN preferentially localizes to uropods in migrating lymphocytes, directly binds to the cytoplasmic tail of aL-integrin, and keeps LFA-1 inactive in these cells. Thereby, SHARPIN regulates uropod detachment and locomotion and transendothelial migration of inflammatory cells. Our findings challenge the prevailing dogma that the inactive LFA-1 is the passive default form of the molecule by showing that active interaction with endogenous SHARPIN is required to maintain LFA-1 in the nonactivated state. (HogenEsch et al., 1993; Seymour et al., 2007) were maintained using heterozygote breedings. Sex-matched littermate wild-type and Sharpin cpdm animals (6-8 weeks) were used in all experiments.
The animal studies were approved by the Animal Experiment Board in Finland. Mouse splenocytes and thymocytes were isolated using mechanical teasing and CD4+ T cells purified by negative selections. Human PBMC and mouse lymphocytes were transfected with plasmids and siRNAs using human and mouse T cell nucleofection kits (Amaxa).
Adhesion and Migration Assays and Uropod Analyses
Cells were allowed to adhere to precoated wells (5 mg/ml ICAM-1 or poly-L-lysine), washed, fixed, stained with propidium iodide, and quantified with Acumen Explorer laser scanner (TTP LabTech). For migration assays, cells were imaged at 1 to 2 min intervals with or without CXCL12-stimulation on ICAM-1 precoated (0.5-50 mg/ml) wells. Cell area, migration speed, and path length analyses were done with National Institutes of Health (NIH) ImageJ software. The extended uropods (uropod length >33% of cell body diameter) and the duration of uropod attachment was scored from the time-lapse videos. The polarization index of cells was calculated as the ratio of x to y, where x is the longest distance across cells (from head to tail) and y is the greatest width perpendicular to x.
Human and mouse leukocytes adhering or migrating on ICAM-1 were stained for immunofluorescence using earlier-described protocols (Rantala et al., 2011) . Migrating cells were stained with KIM127 and 24 using a 80 s exposure of live cells before fixation . For FACS analysis, cells were labeled using indirect or direct staining techniques and analyzed using FACSCalibur with CellQuest software (BD Biosciences).
Immunoblottings, Immunoprecipitations, Pull-Downs, and FarWestern Assays Immunoblotting and immunoprecipitations were done as described (Mattila et al., 2005) . For the pull-down analysis, the cells were lysed or the recombinant protein diluted in a 2% b-octylglucoside-containing lysis buffer, incubated with 2.5 mM biotinylated integrin-peptides bound to streptavidinSepharose beads, washed, and immunoblotted. For far-western assays, purified proteins were spotted on nitrocellulose membranes, incubated with different GST-SHARPIN proteins in blocking buffer, washed, and detected with GST antibody.
Statistical Analysis
The numerical data are presented as mean ± SEM. Each individual experiment used cells from different persons or different mice. All statistical analyses were performed with two-tailed Student's t test. p < 0.05 was considered significant.
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